Q2 2025 Brainstorm Cell Therapeutics Inc Earnings Call Transcript

Aug 14, 2025 / 12:30 PM GMT

Release Date Price: $0.6035 (-8.00%)

Transcript 10-Q8-K

Key Points

Positve

Brainstorm Cell Therapeutics Inc (BCLI) received FDA clearance to initiate the pivotal Phase 3B clinical trial for Neuron, providing regulatory clarity and a strong foundation for future approval.
The company secured a partnership with Menais Advanced Therapies to enhance its US-based manufacturing capabilities, complementing its collaboration with Pluri Inc in Israel.
A citizen petition filed by ALS patients and family members requests a de novo review of Neuron data, potentially opening new regulatory pathways for approval.
The company reported a decrease in general and administrative expenses, indicating improved cost management.
Brainstorm Cell Therapeutics Inc (BCLI) remains committed to advancing Neuron for ALS patients and progressing its clinical initiatives despite challenges.

Negative

The company transitioned from the Nasdaq to the OTCQB due to non-compliance with Nasdaq's minimum shareholder equity requirement, impacting its market presence.
Brainstorm Cell Therapeutics Inc (BCLI) faced challenges in securing funding, delaying the initiation of the Phase 3B trial and affecting Nasdaq compliance.
The filing of the citizen's petition created a new regulatory dynamic, causing key investors to adopt a wait-and-see approach, impacting funding efforts.
The company was unable to submit an application for non-dilutive funding due to an unexpected pause in the submission timeline and lack of co-funding.
Net loss for the quarter increased compared to the previous year, indicating financial challenges.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BCLI.PK - Brainstorm Cell Therapeutics Inc
Q2 2025 Brainstorm Cell Therapeutics Inc Earnings Call
Aug 14, 2025 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Greetings and welcome to the Brainstorm Cell Therapeutic 2nd quarter 2025 conference call.

At this time, all participants are in a listen-only mode. As a reminder, this call is being recorded, and I would now like to introduce your host for today's call, Michael Wood of Life Sci Advisors. Mr. Wood, you may begin.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, Kelly. Good morning, everyone, and thank you for joining us this morning.

Before passing it off to company management for prepared remarks, I would like to remind

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.